Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance, PK, and Metabolism of [14C]-DC-806 in Healthy Men
NCT06045000Phase 1Completed
- Sponsor
- DICE Therapeutics
- Start
- Sep 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navepdekinra in psoriasis, sponsored by DICE Therapeutics. Primary endpoints: Renal Clearance of DC-806, Renal Clearance of Total Radioactivity and 5 more. Started Sep 2023; status: completed.
02
Drugs
navepdekinra
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06045000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045000.